The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Year: 2025
Type: article
Abstract: Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49-0.85; CON: mean = 0.71, range = 0.44-0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials.
Source: Schizophrenia
Authors: Daniel H. Mathalon, Spero Nicholas, Brian J. Roach, Tashrif Billah, Suzie Lavoie, Thomas Whitford, Holly K. Hamilton, Lauren Addamo, Andrey Anohkin, Tristan Bekinschtein, Aysenil Belger, Kate Buccilli, John Cahill, Ricardo E. Carrión, Stefano Damiani, Ilvana Dzafic, Bjørn H. Ebdrup, Igor Izyurov, Johanna Jarcho, Raoul Jenni, Anna Jo, Sarah Kerins, Clarice Lee, Elizabeth A. Martin, Rocio Mayol-Troncoso, Margaret A. Niznikiewicz, Muhammad Parvaz, Oliver Pogarell, Julio Prieto-Montalvo, Rachel Rabin, David R. Roalf, Jack Rogers, Dean F. Salisbury, Riaz Shaik, Stewart Shankman, Michael C. Stevens, Yi Nam Suen, Nicole C. Swann, Xiaochen Tang, Judy L. Thompson, Ivy Tso, Julian Wenzel, Juan Helen Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Rolando I. Castillo-Passi, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Diaz-Caneja, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Rachel Upthegrove, Swapna K. Verma, Jijun Wang, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Ofer Pasternak, Kang-Ik K. Cho, Michael J. Coleman, Dominic Dwyer, Angela Nunez, Zailyn Tamayo, Stephen J. Wood, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Carrie E. Bearden, Barnaby Nelson, Scott W. Woods, Martha E. Shenton, Accelerating Medicines Partnership® Schizophrenia Program, Gregory A. Light
Institutions: University of California, San Francisco, San Francisco VA Health Care System, San Francisco VA Medical Center, Northern California Institute for Research and Education, Brigham and Women's Hospital, Harvard University, The University of Melbourne, Orygen, UNSW Sydney, University of Minnesota, Washington University in St. Louis, University of Cambridge, University of North Carolina at Chapel Hill, Yale University, Northwell Health, Feinstein Institute for Medical Research, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, University of Pavia, University of Copenhagen, Jena University Hospital, Temple University, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Chonnam National University, King's College London, University of California, Irvine, Universidad Alberto Hurtado, University of Chile, Boston VA Research Institute, Icahn School of Medicine at Mount Sinai, Ludwig-Maximilians-Universität München, Universidad Complutense de Madrid, Instituto de Salud Carlos III, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, Douglas Mental Health University Institute, McGill University, University of Pennsylvania, University of Birmingham, University of Pittsburgh, Northwestern University, University of Hong Kong, University of Oregon, Shanghai Jiao Tong University, Shanghai Mental Health Center, University of Rochester Medicine, The Ohio State University Wexner Medical Center, The Ohio State University, University of Cologne, University Hospital Cologne, National University of Singapore, University of Calgary, Hotchkiss Brain Institute, Birmingham Women’s and Children’s NHS Foundation Trust, University of California San Diego, Universidad del Desarrollo, Clínica Alemana, Oregon Research Institute, Beth Israel Deaconess Medical Center, Seoul National University, Seoul National University Hospital, Hanyang University Seoul Hospital, Hartford Hospital, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Cambridgeshire and Peterborough NHS Foundation Trust, Connecticut Mental Health Center, University of Georgia, University of Oxford, Duke-NUS Medical School, Institute of Mental Health, École de Technologie Supérieure, Massachusetts General Hospital, University of California, Los Angeles, VA San Diego Healthcare System
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,890
Funders: Foundation for the National Institutes of Health, U.S. Department of Health and Human Services, U.S. Department of Veterans Affairs, Brigham and Women's Hospital, Massachusetts General Hospital, Ohio State University, Northwestern University, University of Minnesota, University of Pittsburgh, University of Rochester, Hotchkiss Brain Institute, University of Calgary, Wellcome Trust, University of Oregon, École de technologie supérieure, Duke-NUS Medical School, Birmingham Women's and Children's NHS Foundation Trust, King's College London, University of Oxford, National University of Singapore, University of New South Wales, University of Melbourne, Hanyang University, Seoul National University, Seoul National University Hospital, Université de Lausanne, Centre Hospitalier Universitaire Vaudois, Universität zu Köln, Universitätsklinikum Köln, Universidad de Salamanca, Clínica Alemana de Santiago, National Institutes of Health, University of California, Los Angeles, University of North Carolina at Chapel Hill, University of California, San Diego, Medical Center, University of Rochester, College of Medicine, Seoul National University, Menzies Centre for Australian Studies, King's College London, University of London, National Institute of Mental Health, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles
Awards: Psychosis Risk Evaluation, Data Integration and Computational Technologies (PREDICT): Data Processing, Analysis, and Coordination Center, Accelerating Medicines Partnership in Schizophrenia, G2154372021, G224183405, ProNET: Psychosis-Risk Outcomes Network, G8821194462, Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT)
OpenAlex ID: W4411085665